Loading...
NPI 1881841120 · Bensalem, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Atlantic Diagnostic Laboratories, LLC. is a clinical medical laboratory provider located in Bensalem, Pennsylvania. This profile covers 115 Medicare and 95 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Atlantic Diagnostic Laboratories, LLC. |
| Address | 3520 Progress Dr |
| City | Bensalem |
| State | PA |
| ZIP | 19020 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 19, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $87.1M |
| Medicare | $1.5M |
ATLANTIC DIAGNOSTIC LABORATORIES, LLC. is heavily Medicaid-weighted: lifetime Medicaid revenue is $87.1M compared with total Medicare revenue of $1.5M, indicating the provider operates at a much larger scale on the state Medicaid program than on Medicare. This payer mix suggests the lab’s primary commercial footprint and revenue risk are driven by Medicaid flows rather than Medicare business.
Revenue is highly concentrated in a small set of tests for both payers: the top 3 Medicare codes by revenue account for 47.7% of Medicare receipts, while the top 3 Medicaid codes by revenue account for 87.4% of Medicaid receipts. That concentration on a few codes implies the lab’s financial performance is tightly linked to reimbursement and volume trends for those specific services.
The provider’s commercial profile is dominated by drug-testing services: Medicare top codes include 80307 (19.5% of Medicare revenue), G0480 (15.0%), and G0481 (13.3%), and Medicaid top codes are overwhelmingly 80307 (44.8% of Medicaid revenue) and G0480 (33.3%), with G0481 contributing 9.3%. This code mix (presumptive and definitive drug testing) indicates the operation is structured around high-volume toxicology testing rather than being primarily a small-volume anatomic or pathology lab.
ATLANTIC is a major, outlier-scale performer in state Medicaid drug testing: Medicaid 80307 reports 731.8K claims and $38.8M revenue and ranks #2 of 210 providers in-state (100th percentile; extreme outlier, far above typical state volume), while Medicaid G0480 reports 368.7K claims and $28.8M revenue and also ranks #2 of 132 providers in-state (99th percentile; extreme outlier). On Medicare, 80307 also shows above-typical national volume (ranks #54 of 4760, 99th percentile; notably above typical national volume), so the lab is competitively prominent for toxicology testing at both state and national comparison points.
Beyond toxicology, the lab also processes routine clinical panels and public-health testing at smaller shares: Medicare shows material volumes for 36415, 85025, 80053, 84443, 80061 and Medicaid shows measurable revenue for 85025, 80053, 86803, 87389 and a range of infectious-disease panels. These codes (CBC, CMP, TSH, lipid, hepatitis and STD testing) confirm the business offers broad clinical laboratory capabilities in addition to its high-throughput drug-testing line.
The provider demonstrated high-throughput SARS-CoV-2 testing capability across payers: Medicare lists U0004 with 335 claims and $24.8K revenue (2.0% of Medicare revenue) and Medicaid lists U0004 with 44.8K claims and $3.1M revenue (3.6% of Medicaid revenue), plus Medicaid U0005 with 24.8K claims and $447.1K revenue (0.5%). These volumes indicate the lab scaled molecular diagnostic capacity for pandemic-era testing alongside its core toxicology services.
Operational footprints for specimen collection are visible in both claims sets: Medicare items G0471 (2.9K claims, $28.9K revenue, 2.3% of Medicare revenue) and P9604 (1.9K claims, $20.7K revenue, 1.6%) point to venipuncture and trip-based home/nursing home collection activity, and Medicaid includes G2023 specimen collection (10.7K claims, $85.3K revenue). The presence of these collection codes suggests the lab maintains field collection or contracted collection relationships to support community and SNF/HHA workflows.
The organization has an established operating history, with an NPI enumerated on 2008-08-19 (~18 years ago), which together with the extreme Medicaid volumes for a narrow set of codes suggests a long-standing, specialized laboratory positioned as a dominant state Medicaid toxicology supplier while maintaining notable national standing on select Medicare drug-testing codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
115 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 4,030 | $60 | $245.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,690 | $110 | $189.4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,090 | $150 | $167.4K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 13,150 | $10 | $105.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 10,040 | $10 | $80.3K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 6,810 | $10 | $68.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 3,740 | $20 | $59.8K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 4,500 | $10 | $58.4K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 1,700 | $30 | $49.3K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 3,040 | $10 | $30.4K |
Showing 1–10 of 115
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 115 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
115 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 36 | 40 | 1,250 | $30 | $1.1M |
| G0471 | 3 | 10 | 17,570 | $10 | $148.1K |
| U0004 | 5 | 10 | 190 | $70 | $105.8K |
| G0480 | 6 | 40 | 270 | $110 | $94.5K |
| 87493 | 9 | 10 | 110 | $40 | $79.7K |
| P9604 | 8 | 20 | 370 | $10 | $50.6K |
| 80307 | 4 | 100 | 300 | $60 | $42.6K |
| G0481 | 2 | 60 | 100 | $150 | $37.4K |
| G2023 | 7 | 10 | 160 | $20 | $36.4K |
| 87591 | 19 | 20 | 210 | $30 | $34.2K |
Showing 1–10 of 115
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
95 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 731,760 | $50 | $38.8M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 368,710 | $80 | $28.8M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 82,640 | $100 | $8M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 44,760 | $70 | $3.1M |
| 80100 | N/A | 139,550 | $20 | $2.1M |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 74,330 | $10 | $743.3K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 53,890 | $10 | $538.9K |
| 86803 | Qualitative or Semiquantitative Immunoassays; Hepatitis C antibody | 29,890 | $20 | $508.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 24,840 | $20 | $447.1K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 19,110 | $20 | $439.6K |
Showing 1–10 of 95
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
95 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 20 | 710 | $80 | $1.7M |
| 80100 | N/A | 1 | 10 | 90,580 | $20 | $1.4M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 130 | 310 | $60 | $769.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2 | 210 | 730 | $40 | $689.7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 4 | 70 | 620 | $60 | $464.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 13 | 20 | 540 | $50 | $367.6K |
| 86781 | N/A | 1 | 10 | 15,350 | $20 | $280.4K |
| 80101 | N/A | 2 | 10 | 13,550 | $20 | $203.8K |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 11 | 10 | 70 | $150 | $154.4K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 51 | 70 | 320 | $90 | $139.3K |
Showing 1–10 of 95
Other providers in the same ZIP code as Atlantic Diagnostic Laboratories, LLC., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.